One partner, one brand: white-label DNA, gut and blood interpretation, each as its own report under your lab's name. No sequencer in-house? We run DNA and gut testing end to end: you collect, we sequence and interpret DNA and gut, and interpret your blood panels, each as its own report under your lab's name. Your pathologist signs off.
DNA means germline NGS: whole genome, exome, and panels such as drug response (PGx) and carrier screening. Gut microbiome covers 16S and shotgun. For blood, we interpret the panels you already run.
Reports carry the partner laboratory’s brand and are delivered into the LIMS by API and webhooks. Every interpretation traces to 150,000 curated references, and clinical findings are routed to a qualified human. Decision-support, not diagnosis.
Founded in Mumbai in 2015. The engine powers reports for 39 partners across India and 10 other countries. ISO 9001:2015 certified, pursuing ISO 13485, GDPR compliant.
Panel volume is rising faster than capacity to route clinical findings to a qualified human
Report layouts change by vendor, so the laboratory’s name goes out in an inconsistent format
Results sit outside the LIMS when there is no API or webhook on the accession
Standing up interpretation in-house means a specialist team, while the wet-lab is already running
Diagnostic chains are asked for genomics, and a single genotyping file does not standardise the report
Multi-omic interpretation under the partner brand comes first. Wellness modules are available on request.
White-label interpretation layer. Blood, DNA and microbiome, each as its own report under the laboratory’s brand, with API delivery into the LIMS. 150,000 curated references behind every report.
Clinical module already on the platform: gene panels, pharmacogenomics, and whole-exome interpretation. Released as decision-support for the ordering clinician. The Gene Box does not diagnose.
Interpreted blood reports on panels the laboratory already runs. Commercial terms are agreed on the pilot call.
Prism (wellness genomics) and Flora (gut microbiome) can be added to a menu when a laboratory asks for them. They are not the hero of a diagnostic-laboratory deployment.
This page is for the people who own the menu, routing of clinical findings, the accession, and the partnership.
The laboratory keeps the client relationship and the wet-lab. The Gene Box supplies the interpretation layer: blood, DNA and microbiome, each as its own report, with your logo, colours, header, footer, and domain.
White-label content languages already listed on the API page are English, Arabic, and Turkish. The patient-facing and clinician-facing depth can be set by role. The report is still decision-support: it does not replace the ordering clinician.
The published integration path is REST and JSON, OAuth 2.0, a sandbox, and webhooks when a report is ready. HL7/FHIR R4-compatible exchange is described for EHR and LIS integration. Public endpoint families include /v1/samples, /v1/reports/{id}, microbiome routes, and blood overlay.
The example payload in the proof packet uses those public names. It is an illustrative schema for a scoping conversation. It is not a production contract, and it contains no credentials.
Every interpretation is traced to evidence, and clinical findings are routed to a qualified human. The Gene Box does not diagnose. The report is not a medical diagnosis, and the ordering clinician stays responsible for the clinical conversation.
The platform is an interpretation layer for laboratories that already run assays. It is an informatics partnership: your measurement, our reading, your brand on the report.
Two paths are published today. A RESTful API into the systems you already run, and a white-label platform on your domain. The API page describes API onboarding in days and white-label configuration in weeks. The FAQ describes a laboratory partnership cycle in months. Those sentences are inputs to scoping. They are not a service-level agreement. The call sets the calendar.
Bring the LIMS owner and whoever signs reports. The session maps accessions, the webhook destination, brand files, and the path for routing clinical findings to a qualified human. The scoping outline in the proof packet is the agenda.
Sample layout, example payload, scoping agenda, and the compliance line already used on this site. No customer logos and no case studies.
Commercial terms are agreed on the pilot call.
Walk a partner-branded report layout and the decision-support boundary with the people who sign reports.
Accession identifiers, webhook destination, and the sandbox. No production credentials on the call.
Logo, domain, report header and footer, and where clinical findings are routed to a qualified human.
Commercial terms are agreed on the pilot call. This outline is not an SLA.
Walk a partner-branded report layout and the decision-support boundary with the people who sign reports.
Accession identifiers, webhook destination, and the sandbox. No production credentials on the call.
Logo, domain, report header and footer, and where clinical findings are routed to a qualified human.
Commercial terms are agreed on the pilot call. This outline is not an SLA.
Founded in Mumbai in 2015. The engine powers reports for 39 partners across 11 countries. Interpretations trace to 150,000 curated references and 1,200+ validated biomarkers. ISO 9001:2015 certified, pursuing ISO 13485, GDPR compliant. Decision-support, not diagnosis — every interpretation traced to evidence, and clinical findings are routed to a qualified human. The homepage logo row for sequencing infrastructure is described there as industry-standard, not an endorsement. This page does not add named laboratory customers or accreditation counts.
One path for diagnostic laboratories: LIMS delivery, separate DNA, microbiome and blood reports under your brand, and clinical findings routed to a qualified human. Bring lab operations. Leave with a scoping agenda.
